While fecal microbiota transplants are recommended for multiple recurrent Clostridioides difficile infection, their use in clinical practice is hindered by a lack of regulation and understanding of the underlying ecological dynamics. This article covers major challenges for the treatment in transitioning from bench to bedside, from the scientific, clinical and regulatory perspectives (Part 6).